ORIC Pharmaceuticals, Inc.
ORIC
$13.87
$0.151.09%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.70% | 1.29% | 14.41% | 10.99% | 20.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.95% | 21.09% | -12.68% | -4.30% | 8.46% |
| Operating Income | -15.95% | -21.09% | 12.68% | 4.30% | -8.46% |
| Income Before Tax | -14.13% | -19.14% | 15.98% | 5.73% | -13.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.13% | -19.14% | 15.98% | 5.73% | -13.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.13% | -19.14% | 15.98% | 5.73% | -13.74% |
| EBIT | -15.95% | -21.09% | 12.68% | 4.30% | -8.46% |
| EBITDA | -16.20% | -21.39% | 12.82% | 4.38% | -8.42% |
| EPS Basic | 17.45% | 19.76% | 42.13% | 32.80% | -2.40% |
| Normalized Basic EPS | 17.43% | 19.77% | 42.12% | 32.81% | -2.39% |
| EPS Diluted | 17.45% | 19.76% | 42.13% | 32.80% | -2.40% |
| Normalized Diluted EPS | 17.43% | 19.77% | 42.12% | 32.81% | -2.39% |
| Average Basic Shares Outstanding | 38.25% | 48.47% | 45.20% | 40.27% | 11.06% |
| Average Diluted Shares Outstanding | 38.25% | 48.47% | 45.20% | 40.27% | 11.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |